The bill, the Protecting Patients from Deceptive Drugs Online Act, would give the FDA the authority to issue warnings and impose fines on individuals and companies posting false or incomplete information about medications, The Wall Street Journal reported Sept. 12.
Current FDA regulations require drug advertisements from pharmaceutical companies to disclose side effects, but no requirements apply to telehealth firms and influencers who are not directly connected to drugmakers.
Under the proposed bill, the FDA could fine influencers and telehealth companies up to $250,000 for the first violation and $500,000 for subsequent violations within a three-year period. The legislation also would require drugmakers to disclose payments made to influencers, the report said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.